Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

20
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
20
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Therapeutic immune tolerance for central nervous system autoimmune diseases - Prospects, challenges and pitfalls.

Seminars in immunology·2026
Same author

Distinct Clinico-pathogenic Subgroups in Pediatric Lyme Neuroborreliosis.

Open forum infectious diseases·2026
Same author

Monitoring morphometric drift in lifelong learning segmentation of the spinal cord.

Imaging neuroscience (Cambridge, Mass.)·2026
Same author

Anoctamin-2-specific T cells link Epstein-Barr virus to multiple sclerosis.

Cell·2026
Same author

EBV infection and HLA-DR15 jointly drive multiple sclerosis by myelin peptide presentation.

Cell·2026
Same author

Protocol for the characterization of autoproliferating B and T cells from persons with multiple sclerosis.

STAR protocols·2025

Related Experiment Video

Updated: Apr 30, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.0K

Daclizumab (anti-CD25) in multiple sclerosis.

Nikolai Pfender1, Roland Martin1

  • 1Neuroimmunology and MS Research, Department of Neurology, University Hospital Zurich, University Zurich, Frauenklinikstrasse 26, 8091 Zurich, Switzerland.

Experimental Neurology
|April 29, 2014
PubMed
Summary

Daclizumab, an IL-2 receptor antibody, shows promise in treating multiple sclerosis (MS) by reducing disease activity and CNS inflammation. Further research is exploring its novel mechanisms of action in immune regulation.

Keywords:
Anti-CD25DaclizumabImmunomodulatory therapyMonoclonal antibody treatmentMultiple sclerosis

More Related Videos

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

7.2K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.1K

Related Experiment Videos

Last Updated: Apr 30, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.0K
Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease
08:27

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

7.2K
Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics DCAF

Published on: September 17, 2019

6.1K

Area of Science:

  • Immunology
  • Neuroscience
  • Pharmacology

Background:

  • Multiple sclerosis (MS) is an autoimmune CNS disorder characterized by inflammation and neurodegeneration.
  • Current MS treatments offer moderate efficacy; novel therapies with superior efficacy are needed.
  • Daclizumab, an IL-2 receptor (CD25) antibody, is a potential new therapeutic agent for MS.

Purpose of the Study:

  • To evaluate the clinical efficacy and safety of daclizumab in patients with multiple sclerosis.
  • To investigate the immunological mechanisms underlying daclizumab's therapeutic effects in MS.

Main Methods:

  • Clinical trials, including phase II studies with over 900 patients, assessed daclizumab's efficacy in reducing MS disease activity and CNS inflammation.
  • Mechanistic studies analyzed daclizumab's impact on immune cells, including T cells, natural killer (NK) cells, and dendritic cells (DCs).

Main Results:

  • Daclizumab demonstrated efficacy in reducing clinical disease activity and CNS inflammation in MS patients.
  • Mechanistic studies revealed daclizumab's multifaceted action, including T cell modulation, NK cell expansion, and effects on DC-T cell interactions.
  • Safety data from kidney transplantation and MS trials appear favorable.

Conclusions:

  • Daclizumab represents a promising therapeutic option for multiple sclerosis, with demonstrated clinical efficacy and a favorable safety profile.
  • Daclizumab's mechanism of action involves complex immunomodulatory effects beyond simple T cell blockade.
  • Ongoing phase III trials will further define daclizumab's role in MS management.